Skip to main content
. 2010 May 3;28(16):2768–2776. doi: 10.1200/JCO.2009.23.8931

Fig 2.

Fig 2.

Endoxifen concentration according to CYP2D6 activity. (A) Endoxifen concentrations (nmol/L) in tamoxifen-treated women based on CYP2D6 functional alleles. (B) Endoxifen concentrations in tamoxifen-treated women who are CYP2D6 extensive metabolizers and who were coprescribed venlafaxine (not a CYP2D6 inhibitor), sertraline and citalopram (weak CYP2D6 inhibitors), or fluoxetine and paroxetine (potent CYP2D6 inhibitors). Modified with permission.7

HHS Vulnerability Disclosure